Xbrane Biopharma

Xbrane Biopharma Enterprise Value

The Enterprise Value (EV) of Xbrane Biopharma (XBRANE.ST) as of Oct 19, 2026 is 97.14 M SEK. In the previous year, Enterprise Value (EV) was 192.81 M SEK — a change of -49.62% (lower).

Enterprise Value

97.14 MSEK

YoY

-49.62%

Last updated:

Enterprise Value (EV) of Xbrane Biopharma is 2025 97.14 M SEK. Enterprise Value (EV) of Xbrane Biopharma was 2024 192.81 M SEK. It decreases by -49.62% lower compared to the previous year.

The Xbrane Biopharma Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2018
70.05 M SEK
Jan 1, 2019
-29.34 M SEK
Jan 1, 2020
-111.46 M SEK
Jan 1, 2021
-125.38 M SEK
Jan 1, 2022
-30.35 M SEK
Jan 1, 2023
291.50 M SEK
Jan 1, 2024
192.81 M SEK
Jan 1, 2025
97.14 M SEK
The Xbrane Biopharma Enterprise Value history
YEAREnterprise ValueYoY
97.14 MSEK-49.62%
192.81 MSEK-33.86%
291.50 MSEK-1,060.32%
-30.35 MSEK-75.79%
-125.38 MSEK+12.49%
-111.46 MSEK+279.89%
-29.34 MSEK-141.88%
70.05 MSEK-40.95%
118.64 MSEK+23.83%
95.81 MSEK-27.96%
133.00 MSEK+2.71%
129.48 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Xbrane Biopharma Stock analysis

What does Xbrane Biopharma do? Xbrane Biopharma AB, based in Solna, Sweden, operates in the Health Care sector as a biotechnology company specializing in the development and manufacturing of biosimilars. The company employs 92 full-time staff and focuses on injectable slow-release drugs and high-yield protein expression technology. Key products include Sperotide, a biosimilar to Decapeptyl, Trelstar, and Pamorelin, and Xlucane, a biosimilar to Lucentis, both developed for injectable use. Xbrane Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Xbrane Biopharma stock

Enterprise Value (EV) of Xbrane Biopharma is 97.14 M SEK in 2025.

Enterprise Value (EV) of Xbrane Biopharma changed from 192.81 M SEK to 97.14 M SEK, representing a -49.62% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) Xbrane Biopharma since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s SEK, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' SEK varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s Xbrane Biopharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Xbrane Biopharma

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Xbrane Biopharma